miRNA-Seq Tissue Diagnostic Signature: A Novel Model for NSCLC Subtyping

Radosław Charkiewicz, Anetta Sulewska, Alicja Charkiewicz, Attila Gyenesei, Bence Gálik, Rodryg Ramlau, Cezary Piwkowski, Rafał Stec, Przemysław Biecek, Piotr Karabowicz, Anna Michalska‐Falkowska, Wojciech Miltyk, Jacek NiklińskiInternational Journal of Molecular Sciences 2023 · DOI

TL;DR

This study introduces a novel molecular diagnostic model using microRNA (miRNA) expression profiles from tumor tissue to accurately distinguish between the two main subtypes of non-small cell lung cancer (NSCLC): adenocarcinoma (AC) and squamous cell carcinoma (SCC). The developed 17-miRNA signature achieved an impressive diagnostic accuracy, paving the way for more personalized treatment strategies.

What Problem Does This Paper Address?

Non-small cell lung cancer (NSCLC) is a complex disease with distinct subtypes, primarily adenocarcinoma (AC) and squamous cell carcinoma (SCC). These subtypes have different molecular characteristics, clinical behaviors, and responses to treatment. Accurate differentiation is crucial for effective, personalized therapy, especially with the rise of targeted treatments that are often subtype-specific. While traditional histopathology is the current standard, it can be challenging and prone to inaccuracies, with an estimated 15-20% of cases being difficult to classify definitively. This ambiguity can lead to suboptimal treatment decisions. The paper aims to address this by developing a more precise and objective molecular diagnostic tool.

Methods

The researchers employed a multi-step approach to identify and validate a miRNA signature for NSCLC subtyping.

  • Next-Generation Sequencing (NGS): They used miRNA-Seq to analyze the expression profiles of miRNAs in tumor tissue samples from AC and SCC patients.
  • Differential Expression Analysis: Standard statistical methods, including Limma package with modified t-tests and false discovery rate (FDR) correction, were used to identify miRNAs with significantly different expression levels between AC and SCC.
  • LASSO/Elastic Net Regression: To build a robust and parsimonious signature, LASSO/elastic net regression was applied. This technique is effective for feature selection and model building, especially in high-dimensional data like gene expression, helping to identify the most predictive miRNAs while minimizing overfitting.
  • Receiver Operating Characteristic (ROC) Curve Analysis: The diagnostic utility of the identified miRNA signature was evaluated using ROC curves, a standard method for assessing the performance of binary classification models. The area under the curve (AUC) was calculated to quantify the overall accuracy.

Datasets

The study utilized a dataset of 59 surgically resected non-small cell lung cancer (NSCLC) cases.

  • 31 cases (52.5%) were histologically diagnosed as squamous cell carcinoma (SCC).
  • 28 cases (47.5%) were histologically diagnosed as adenocarcinoma (AC). The paper does not mention the creation of a new benchmark dataset; rather, it uses existing patient samples for analysis and validation.

Key Insights and Ideas

  • miRNAs as potent biomarkers: The study reinforces the idea that miRNAs, small non-coding RNAs involved in gene regulation, can serve as highly specific biomarkers for cancer subtypes. Their expression patterns can reflect the underlying molecular differences between AC and SCC.
  • Beyond Histopathology: The research highlights the limitations of traditional histopathology and proposes a molecular approach that offers greater precision and objectivity, potentially overcoming diagnostic ambiguities.
  • The Power of a Signature: Instead of relying on individual miRNAs, the study demonstrates that a carefully selected panel of miRNAs (a "signature") can collectively provide a powerful diagnostic signal.
  • LASSO for robust feature selection: The use of LASSO/elastic net regression is a key methodological insight, enabling the identification of a concise yet highly accurate miRNA signature from a larger pool of differentially expressed miRNAs.

Key Results

  • 31 Differentially Expressed miRNAs: Initially, 31 miRNAs were identified as showing significant differential expression between AC and SCC. Of these, 27 were downregulated in AC compared to SCC.
  • 17-miRNA Signature: A refined signature of 17 miRNAs was constructed using LASSO/elastic net regression. This signature includes both upregulated and downregulated miRNAs.
  • Exceptional Diagnostic Performance: The 17-miRNA signature demonstrated remarkable diagnostic capability, achieving an Area Under the Curve (AUC) of 0.994 in ROC curve analysis. This indicates a near-perfect ability to discriminate between AC and SCC.
  • Previously Implicated miRNAs: Several miRNAs in the signature, such as hsa-miR-326, hsa-miR-375, hsa-miR-944, and hsa-miR-205-5p, have been previously linked to lung cancer pathogenesis and progression, lending further credibility to their role in subtyping.

Limitations and Future Work

  • Sample Size: While the study included 59 cases, the authors acknowledge that expanding the cohort for further validation would be beneficial to confirm the diagnostic potential of the miRNA signature.
  • Functional Studies: The paper suggests that conducting functional studies to investigate the specific mechanistic roles of these miRNAs in lung cancer subtypes would provide deeper insights into their biological significance.
  • Clinical Translation: The authors emphasize that further validation and prospective clinical trials are necessary to confirm the clinical utility of the 17-miRNA signature and its integration into routine practice for patient management. They envision its use in guiding personalized treatment decisions, particularly in the context of neoadjuvant therapies.

Summary updated

Abstract

Non-small cell lung cancer (NSCLC) encompasses distinct histopathological subtypes, namely adenocarcinoma (AC) and squamous cell lung carcinoma (SCC), which require precise differentiation for effective treatment strategies. In this study, we present a novel molecular diagnostic model that integrates tissue-specific expression profiles of microRNAs (miRNAs) obtained through next-generation sequencing (NGS) to discriminate between AC and SCC subtypes of NSCLC. This approach offers a more comprehensive and precise molecular characterization compared to conventional methods such as histopathology or immunohistochemistry. Firstly, we identified 31 miRNAs with significant differential expression between AC and SCC cases. Subsequently, we constructed a 17-miRNA signature through rigorous multistep analyses, including LASSO/elastic net regression. The signature includes both upregulated miRNAs (hsa-miR-326, hsa-miR-450a-5p, hsa-miR-1287-5p, hsa-miR-556-5p, hsa-miR-542-3p, hsa-miR-30b-5p, hsa-miR-4728-3p, hsa-miR-450a-1-3p, hsa-miR-375, hsa-miR-147b, hsa-miR-7705, and hsa-miR-653-3p) and downregulated miRNAs (hsa-miR-944, hsa-miR-205-5p, hsa-miR-205-3p, hsa-miR-149-5p, and hsa-miR-6510-3p). To assess the discriminative capability of the 17-miRNA signature, we performed receiver operating characteristic (ROC) curve analysis, which demonstrated an impressive area under the curve (AUC) value of 0.994. Our findings highlight the exceptional diagnostic performance of the miRNA signature as a stratifying biomarker for distinguishing between AC and SCC subtypes in lung cancer. The developed molecular diagnostic model holds promise for providing a more accurate and comprehensive molecular characterization of NSCLC, thereby guiding personalized treatment decisions and improving clinical management and prognosis for patients.
BibTeX
@article{charkiewicz2023mirna,
  author = {Radosław Charkiewicz and Anetta Sulewska and Alicja Charkiewicz and Attila Gyenesei and Bence Gálik and Rodryg Ramlau and Cezary Piwkowski and Rafał Stec and Przemysław Biecek and Piotr Karabowicz and Anna Michalska‐Falkowska and Wojciech Miltyk and Jacek Nikliński},
  title = {{miRNA-Seq Tissue Diagnostic Signature: A Novel Model for NSCLC Subtyping}},
  journal = {International Journal of Molecular Sciences},
  year = {2023},
  doi = {10.3390/ijms241713318},
}
Figure